ClinicalTrials.gov
public full text
Public Domain
Phased Treatment for Social Anxiety Disorder and Coping Behaviors in a Medical Setting
The purpose of this study is to treat individuals with social anxiety disorder with a Food and Drug Administration-approved medication for the treatment of social anxiety disorder, the antidepressant paroxetine, and to evaluate the impact of an intervention designed to help those individuals cope with anxiety without the use of common coping behaviors.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Cognitive-behavioral Therapy for Generalized Anxiety Disorder in Primary Care#1127116
- Stepped Care for Treating Obsessive-Compulsive Disorder#852069
- Treatment and Pharmacology of Anxiety From Classical Antiquity to the Present Day: Methods and Therapeutic Practices.#547
- Internet-Delivered Cognitive Behavioral Therapy for Social Anxiety Disorder: Nationwide Retrospective Cohort Observational Study#784487
- Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia#856897
Record · ID 875683
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive